Findings indicate BAG3 modulation after traumatic brain injury may mitigate tau buildup and cognitive deficits, presenting a target for Alzheimer’s prevention.
IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL
The FDA approved denileukin diftitox (Lymphir), the first novel targeted systemic therapy approved for relapsed/refractory (r/r) cutaneous T-cell lymphoma (CTCL) since 2018, Citius Pharmaceuticals announced.